Pulmonary drug delivery with aerogels: engineering of alginate and alginate–hyaluronic acid microspheres

Hydrogels warrant attention as a potential material for use in sustained pulmonary drug delivery due to their swelling and mucoadhesive features. Herein, hyaluronic acid (HA) is considered a promising material due to its therapeutic potential, the effect on lung inflammation, and possible utility as an excipient or drug carrier. In this study, the feasibility of using HA hydrogels (without a model drug) to engineer inhalation powders for controlled pulmonary drug delivery was assessed. A combination of chemical crosslinking and spray-drying was proposed as a novel methodology for the preparation of inhalation powders. Different crosslinkers (urea; UR and glutaraldehyde; GA) were exploited in the hydrogel formulation and the obtained powders were subjected to extensive characterization. Compositional analysis of the powders indicated a crosslinked structure of the hydrogels with sufficient thermal stability to withstand spray drying. The obtained microparticles presented a spherical shape with mean diameter particle sizes from 2.3 ± 1.1 to 3.2 ± 2.9 μm. Microparticles formed from HA crosslinked with GA exhibited a reasonable aerosolization performance (fine particle fraction estimated as 28 ± 2%), whereas lower values were obtained for the UR-based formulation. Likewise, swelling and stability in water were larger for GA than for UR, for which the results were very similar to those obtained for native (not crosslinked) HA. In conclusion, microparticles could successfully be produced from crosslinked HA, and the ones crosslinked by GA exhibited superior performance in terms of aerosolization and swelling.

Download Full-text

Pulmonary Drug Delivery Systems: Recent Developments and Prospects;

Critical Reviews in Therapeutic Drug Carrier Systems ◽

10.1615/critrevtherdrugcarriersyst.v19.i45.40 ◽

2002 ◽

Vol 19 (4-5) ◽

pp. 425-498 ◽

Cited By ~ 185

Author(s):

H. M. Courrier ◽

N. Butz ◽

Th. F. Vandamme

Keyword(s):

Drug Delivery ◽

Drug Delivery Systems ◽

Delivery Systems ◽

Pulmonary Drug Delivery ◽

Recent Developments

Download Full-text

Recent Advances in the Development of Polymeric Nanocarrier Formulations for the Treatment of Colon Cancer

Drug Delivery Letters ◽

10.2174/2210303108666181109120710 ◽

2019 ◽

Vol 9 (1) ◽

pp. 2-14

Author(s):

Sahil Kumar ◽

Bandna Sharma ◽

Kiran Thakur ◽

Tilak R. Bhardwaj ◽

Deo N. Prasad ◽

...

Keyword(s):

Drug Delivery ◽

Colon Cancer ◽

Hyaluronic Acid ◽

Targeted Drug Delivery ◽

Drug Delivery Systems ◽

Delivery Systems ◽

Near Ir ◽

Targeted Drug ◽

Poly Ethylene ◽

Novel Drug

Background: Many efforts have been explored in the last decade to treat colon cancer but nanoparticulate drug delivery systems are making a vital contribution in the improvement of drug delivery to colon cancer cells. Objective: In this review, we attempt to highlight recent advancements in the development of novel drug delivery systems of nanoparticles for the targeted drug delivery to colon. Polymers like Epithelial Cell Adhesion Molecule (EpCAM) aptamer chitosan, Hyaluronic Acid (HA), Chitosan (CS)– Carboxymethyl Starch (CMS), silsesquioxane capped mesoporous silica, Near IR (NIR) fluorescent Human Serum Albumin (HAS), poly(ethylene glycol)-conjugated hyaluronic acid etc. have been discussed by employing various anticancer drugs like doxorubicin, oxaliplatin, paclitaxel, 5-fluorouracil etc. Conclusion: These novel drug delivery systems have been determined to be more efficacious in terms of stability, sustained and targeted drug delivery, therapeutic efficacy, improved bioavailability and enhanced anticancer activity.

Download Full-text

Application of Chitosan and its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems

Pharmaceutical Nanotechnology ◽

10.2174/2211738505666170808095258 ◽

2018 ◽

Vol 5 (4) ◽

Cited By ~ 2

Author(s):

Kamal Dua ◽

Mary Bebawy ◽

Rajendra Awasthi ◽

Rakesh K. Tekade ◽

Muktika Tekade ◽

...

Keyword(s):

Drug Delivery ◽

Drug Delivery Systems ◽

Delivery Systems ◽

Pulmonary Drug Delivery

Download Full-text

Polyhydroxyalkanoate Nanoparticles for Pulmonary Drug Delivery: Interaction with Lung Surfactant

Nanomaterials ◽

10.3390/nano11061482 ◽

2021 ◽

Vol 11 (6) ◽

pp. 1482

Author(s):

Olga Cañadas ◽

Andrea García-García ◽

M. Auxiliadora Prieto ◽

Jesús Pérez-Gil

Keyword(s):

Drug Delivery ◽

Drug Delivery Systems ◽

Bacterial Species ◽

High Surface ◽

Lung Surfactant ◽

Delivery Systems ◽

Pulmonary Drug Delivery ◽

Epifluorescence Microscopy ◽

Energy Storage Materials ◽

The Stability

Polyhydroxyalkanoates (PHA) are polyesters produced intracellularly by many bacterial species as energy storage materials, which are used in biomedical applications, including drug delivery systems, due to their biocompatibility and biodegradability. In this study, we evaluated the potential application of this nanomaterial as a basis of inhaled drug delivery systems. To that end, we assessed the possible interaction between PHA nanoparticles (NPs) and pulmonary surfactant using dynamic light scattering, Langmuir balances, and epifluorescence microscopy. Our results demonstrate that NPs deposited onto preformed monolayers of DPPC or DPPC/POPG bind these surfactant lipids. This interaction facilitated the translocation of the nanomaterial towards the aqueous subphase, with the subsequent loss of lipid from the interface. NPs that remained at the interface associated with liquid expanded (LE)/tilted condensed (TC) phase boundaries, decreasing the size of condensed domains and promoting the intermixing of TC and LE phases at submicroscopic scale. This provided the stability necessary for attaining high surface pressures upon compression, countering the destabilization induced by lipid loss. These effects were observed only for high NP loads, suggesting a limit for the use of these NPs in pulmonary drug delivery.

Download Full-text